ClinicalTrials.gg

Program

rezpegaldesleukin

Also written as “LY3471851” and “Rezpegaldesleukin”.

Its studies are mostly in Dermatitis, Atopic · Lupus Erythematosus, Systemic · Alopecia Areata · Psoriasis · Colitis, Ulcerative, led by Nektar Therapeutics.

Furthest: phase 3, since Jul 2, 202613 company-led studies, 3 open or runningNext primary completion: May 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Nektar Therapeutics133 open or runningphase 3since Jul 2, 2026May 7, 2018May 2028phase 3 · NCT07690371

Also a collaborator on its studies: Eli Lilly.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 7, 2018First study: phase 1 study in Lupus Erythematosus, SystemicFirst studyNCT03556007 · 48 enrolled · United States
  2. Sep 5, 2019Phase 1 study in Dermatitis, AtopicNCT04081350 · 48 enrolled · United States
  3. Oct 7, 20192 phase 1 studiesNCT04119557, NCT04133116
  4. May 6, 2020Phase 1 study in HealthyNCT04380324 · 100 enrolled · United States
  5. Jun 15, 2020Phase 2 study in Lupus Erythematosus, SystemicNCT04433585 · 291 enrolled · United States, Argentina, Australia and more
  6. Dec 8, 2020Phase 2 study in Colitis, UlcerativeNCT04677179 · 81 enrolled · United States, Argentina, Australia and more
  7. Aug 9, 2021Phase 1 study in HealthyNCT04998487 · 71 enrolled · United States
  8. Oct 3, 2022Phase 1 study in HealthyNCT05565729 · 41 enrolled · United States
  9. Nov 13, 2023Phase 2 study in Moderate to Severe Atopic DermatitisNCT06136741 · 396 enrolled · United States, Australia, Bulgaria and more
  10. Mar 25, 2024Phase 2 study in Alopecia AreataNCT06340360 · 94 enrolled · United States, Canada, Poland
  11. Jul 2, 20262 phase 3 studies in Moderate-to-Severe Atopic DermatitisPhase 3 reachedNCT07690371, NCT07711418

Ahead

  1. May 2028Primary completion: phase 3 study in Moderate-to-Severe Atopic DermatitisNCT07690371
  2. Jun 2028Primary completion: phase 3 study in Moderate-to-Severe Atopic DermatitisNCT07711418

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07711418Moderate-to-Severe Atopic Dermatitis · United States3RecruitingJun 2028510
NCT07690371Moderate-to-Severe Atopic Dermatitis · United States3RecruitingMay 2028510
NCT06340360Alopecia Areata · United States, Canada, Poland2CompletedNov 26, 202594
NCT06136741Moderate to Severe Atopic Dermatitis · United States, Australia, Bulgaria and more2Active, not recruitingMay 6, 2025396
NCT05565729Healthy · United States1CompletedFeb 23, 202341
NCT04998487Healthy · United States1CompletedJul 6, 202271
NCT04677179Colitis, Ulcerative · United States, Argentina, Australia and more2TerminatedAug 9, 202281
NCT04433585Lupus Erythematosus, Systemic · United States, Argentina, Australia and more2CompletedJan 10, 2023291
NCT04380324Healthy · United States1CompletedJan 20, 2019100
NCT04133116Healthy · United States1CompletedMar 6, 202036
NCT04119557Psoriasis · United States1CompletedJul 21, 202130
NCT04081350Dermatitis, Atopic · United States1CompletedJun 24, 202248
NCT03556007Lupus Erythematosus, Systemic · United States1CompletedAug 29, 201948

How it is read

Names in the registry

  • “LY3471851”, 9 entries
  • “Rezpegaldesleukin”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.